In the eyes of economic policymakers and biotech experts, the generic market is a dependable but plodding source of income that offers no prospects for truly eye-popping profits.
因此看在經建官員與生技學者的眼裡，學名藥是個不具爆發力，不會餓死、但也賺不了大錢的產業。